Paper Details

  1. Home
  2. Paper Details

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.

Author: , KavanaughArthur, KirkhamBruce, LandewéRobert, McInnesIain B, MeasePhilip J, MpofuShephard, NashPeter, PricopLuminita, RahmanProton, RichardsHanno B, YuanJiacheng, van der HeijdeDésirée

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Secukinumab was more effective than placebo in patients with psoriatic arthritis, which validates interleukin-17A as a therapeutic target. The ACR20 response rates at week 24 were significantly higher in the group receiving secukinumab at doses of 150 mg (50.0%) and 75 mg (50.5%) than in those receiving placebo (17.3%). Infections, including candida, were more common in the secukinumab groups than in the placebo group.
Paper Details　
Original Abstract of the Article :
BACKGROUND: In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs and symptoms of psoriatic arthritis. We sought to evaluate the efficacy and safety of secukinumab, an anti-interleukin-17A monoclonal antibody, in such patients. METHODS: In this double-blind, phase 3 stud...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1412679

データ提供：米国国立医学図書館（NLM）

Secukinumab Inhibition of Interleukin-17A for Psoriatic Arthritis

This study explores the potential of [treatment method] for treating psoriatic arthritis (PsA), a chronic inflammatory disease. The researchers conducted a [study type] to evaluate the efficacy and safety of [treatment method], a monoclonal antibody that targets interleukin-17A, in patients with PsA. They discovered that [treatment method] was significantly more effective than placebo in improving signs and symptoms of PsA, including joint tenderness, swelling, and overall disease activity. The study also noted that infections, particularly candida infections, were more common in patients receiving [treatment method].

A Promising Treatment Option for Psoriatic Arthritis

The study's findings suggest that [treatment method] could be a valuable treatment option for many individuals with PsA. The researchers found that [key findings], highlighting the potential benefits of targeting interleukin-17A to alleviate symptoms of this chronic inflammatory disease.

Navigating the Desert of Psoriatic Arthritis

This study underscores the importance of careful consideration and personalized care when treating PsA. While [treatment method] shows promise, it's crucial to weigh the potential benefits against the risks, including the increased risk of infections. The study encourages open communication between patients and healthcare providers to ensure that the most appropriate treatment plan is selected.

Dr.Camel's Conclusion

This study offers a ray of hope in the desert of PsA treatment. [Treatment method] shows promise as a treatment option, offering potential relief for many individuals struggling with this debilitating condition. However, the journey through the desert of PsA is unique for everyone, and we must continue to seek innovative treatments and personalized care to ensure that everyone has access to the support they need to thrive.

Date :
  1. Date Completed 2015-10-08
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

26422723

DOI: Digital Object Identifier

10.1056/NEJMoa1412679

Related Literature

Article Analysis
・Effects of secukinumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.